Metabolic Disorder Therapeutics Market

Metabolic Disorder Therapeutics Market Size, Share, Growth Analysis, By Disease(Lysosomal Storage Diseases, Gaucher’s Disease, Metachromatic Leukodystrophy, Hurler - Scheie), By Therapy Type(Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy), By Regional(North America, The U.S., Canada, Europe) - Industry Forecast 2025-2032


Report ID: UCMIG35I2238 | Region: Global | Published Date: Upcoming |
Pages: 165 | Tables: 55 | Figures: 60

Metabolic Disorder Therapeutics Market Insights

Market Overview:

Initiating at a valuation of USD 49.65 billion in 2017, the global metabolic disorder therapeutics market is poised for an upward trajectory, projected to sustain a notable Compound Annual Growth Rate (CAGR) of 7.56% throughout the forecast period. This ascent is galvanized by a confluence of pivotal factors. The surging demand for one-time therapeutic interventions tailored for metabolic disorders stands as a chief propeller, promising effective treatment regimens for patients. A parallel narrative is woven by the escalating prevalence of lifestyle-related diseases, such as diabetes and obesity, as a result of changing global lifestyles. Projections from governmental bodies and healthcare organizations paint a vivid picture, estimating that over half a billion individuals could be grappling with these conditions by 2040. Moreover, the rising incidence of inherited metabolic disorders, spurred by lifestyle shifts, lends additional impetus to the market's growth, painting a comprehensive landscape poised for positive transformation.

Metabolic Disorder Therapeutics Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028
ForecastGrowthRate
To get more reports on the above market click here to
Get Free Sample

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Pharmaceuticals by segment aggregation, the contribution of the Pharmaceuticals in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The market for Metabolic Disorder Therapeutics was estimated to be valued at US$ XX Mn in 2021.

The Metabolic Disorder Therapeutics Market is estimated to grow at a CAGR of XX% by 2028.

The Metabolic Disorder Therapeutics Market is segmented on the basis of Disease, Therapy Type, Regional.

Based on region, the Metabolic Disorder Therapeutics Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the Metabolic Disorder Therapeutics Market are rview , The metabolic disorder therapeutics market size was valued at USD 49.65 billion in 2017 and is expected to register a CAGR of 7.56% over the forecast period. Increasing demand for one-time therapies for metabolic disorders and the rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market. Various governments and healthcare associations around the world have estimated that more than half a billion individuals are to be affected by obesity and diabetes by 2040. Also, rising incidences of inherited metabolic diseases due to changing lifestyles are likely to propel the market growth. , As has been observed in recent years, the cases of diabetes have been increasing and many of the countries might face a potential metabolic disorder epidemic. Many of the industrial countries are concerned with the chronic obesity epidemic with the U.S. leading in the number of obese cases. In the U.S. alone, an obese person on average spends around USD 1500 on medical expenses. , Over the years, the economic condition has improved, especially in developing countries, which have a high number of cases of metabolic diseases. Researchers are urging governments across the globe to take action and come up with studies and solutions to reduce obesity and diabetes. For instance, scientists say that one in three individuals is obese and there have never been reports stating the reduction in obesity numbers. These factors are driving obesity segment growth. , Other factors that are propelling the market growth are the rapidly aging population, sedentary lifestyles, and increasing cases of smoking and other metabolic pathway restricting practices. Diabetes has become a epidemic with more than 5% of the population affected by the disease requiring constant medication to battle certain fatal conditions. For instance, in 2016, around 1.5 million deaths occurred directly due to diabetes. , Disease Insights , Based on disease, the market is categorized into diabetes, lysosomal disorders, hypercholesterolemia, obesity, and inherited metabolic disorders. These diseases are mostly inherited from the older generation through a faulty gene and some show immediate effects like the lysosomal disorders, while some show up later due to aging. For instance, diabetes might not be diagnosed up to a certain age. , Diabetes was estimated to be the largest segment in 2017 due to the wide usage of metabolic disease therapies in anti-diabetic drugs and injections to control the blood sugar levels. In diabetes, constant ingestion of metabolic regulators is essential. This factor makes it the largest revenue-generating segment. However, the obesity segment is expected to witness the fastest growth over the forecast period due to increasing lifestyle changes and unhealthy eating habits. , Therapy Insights , The therapy segment is further categorized into enzyme replacement therapy, cellular transplantation, substrate reduction therapy, small molecule-based therapy, gene therapy, and drug therapy. Except for drug therapy, all the other therapies are novel and cutting-edge, which makes then more effective in treating metabolic diseases. However, the downside of these therapies is high costs and a lack of solid scientific backup. For instance, enzyme replacement therapy costs around 300,000 per year as the treatment should go on continuously at least once or twice a week. , Thus, drug therapy held the highest market share due to its extensive usage as a result if ease of administration and high-reliability rate. This therapy is expected to maintain its growth even during the forecast period owing to its advanced ways of administering medications without disturbing day-to-day patient lives. Moreover, the introduction of smart drug delivery devices and smart dosage control methods are projected to drive the segment further. , Route of Administration Insights , Based on the route of administration, the market is segmented into oral, parenteral, and other routes of administration. The oral route of administration segment was the key revenue-generating segment due to wide usage in diabetes and hypercholesterolemia treatments. The rise in demand for safe and smart drug delivery has driven the growth in this segment because of the ease of use, reliability, and proven results offered by the oral route of administration. , The other segment is also likely to witness significant growth over the forecast period as researchers are continuously striving for better medication and therapy that can eliminate the need for lifelong diagnosis and multiple dosage therapy. In recent years, due to the advances in diagnostics, greater emphasis on groundbreaking therapies, like gene therapy, has been observed. This is projected to lead the segment growth shortly. , Regional Insights , North America is the dominant region of this market due to the presence of major companies. Increasing prevalence of obesity and diabetes in the region is another factor responsible for its largest share. High healthcare expenditure and rising awareness about metabolic disorders are expected to drive the regional market further. , Asia Pacific is said to witness the fastest CAGR of 8.27% during the estimated time owing to the rapid economic development in this region. Changing lifestyles, leading to a rise in obesity, diabetes, and hypercholesterolemia diseases, along with increased disposable income levels are driving the APAC market. , Market Share Insights , Expansion of product portfolios and M&A are the key strategies undertaken by most of these companies. For instance, in 2017, Boehringer Ingelheim, in collaboration with Eli Lily and Company, had announced positive data about the clinical development of Jardiance for the reduction of cardiovascular deaths in adults with type 2 diabetes and peripheral artery disease. , KEY MARKET SEGMENTS, By Disease, Lysosomal Storage Diseases , Gaucher’s Disease , Metachromatic Leukodystrophy , Hurler - Scheie , Sanfilipo A , Others , Diabetes , Obesity , Inherited Metabolic Disorders , Hypercholesterolemia , By Therapy Type, Enzyme Replacement Therapy , Cellular Transplantation , Small Molecule Based Therapy , Substrate Reduction Therapy , Gene Therapy , Drug Therapy , Route of Administration, Oral , Parenteral , Others , By Regional, North America , The U.S. , Canada , Europe , Germany , U.K. , Asia Pacific , Japan , China , Latin America , Brazil , Middle East & Africa , South Africa , KEY MARKET PLAYERS, Novo Nordisk A/S , Sanofi S.A. , Boehringer Ingelheim GmbH , Eli Lilly and Company , Merck KgaA , Amgen, Inc. , AstraZeneca PLC , Actelion Pharmaceuticals Ltd. , Shire PLC , AbbVie, Inc. , Biocon Ltd. , BioMarin Pharmaceutical, Inc. , Bristol-Myers Squibb Company , Cipla, Inc. , CymaBay Therapeutics, Inc.".

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Metabolic Disorder Therapeutics Market

Report ID: UCMIG35I2238

$5,300
BUY NOW GET FREE SAMPLE